|Bid||5.18 x 2200|
|Ask||5.19 x 3000|
|Day's Range||4.99 - 5.26|
|52 Week Range||1.80 - 12.44|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Clover Biopharmaceuticals, a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced positive clinical data from its Phase 1 trial demonstrating that its protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) induces strong immune responses, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in 150 adult and elderly participants. The manuscript describing the detailed results will be accessible on an online preprint server shortly.
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Dynavax Technologies Corp.
EMERYVILLE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on Monday, September 14, at 10:00 a.m. ET. The presentation will be webcast and may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s website at http://investors.dynavax.com/events-presentations.About Dynavax Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also further developing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.Contacts:Nicole Arndt firstname.lastname@example.org 510-665-7264Derek Cole, President Investor Relations Advisory Solutions derek.cole@IRadvisory.com